AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26286450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a plus ribavirin
Number of subjects: 236
Study 26286544 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-mounted stent
Number of subjects: 300
Study 26286544 — intervention group
Group type: COMPARATOR
Intervention: Balloon plus self-expanding stent
Number of subjects: 300
Study 26286816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone analgesia
Number of subjects: 0
Study 26287849 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib in non-small-cell lung cancer
Number of subjects: 122
Study 26287849 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib in Erdheim-Chester disease or Langerhans'-cell histiocytosis
Number of subjects: 122
Study 26287849 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib and cetuximab in colorectal cancer
Number of subjects: 122
Study 26287849 — intervention group
Group type: EXPERIMENTAL
Intervention: vemurafenib in other cancers (pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, clear-cell sarcoma)
Number of subjects: 122
Study 26288246 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label venlafaxine XR (titrated up to 300 mg/d) for 12 weeks
Number of subjects: 453
Study 26288277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) via single colonoscopic administration
Number of subjects: 7
Study 26288390 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight percentile less than 10% during the year of enrollment
Number of subjects: 484
Study 26288390 — intervention group
Group type: EXPERIMENTAL
Intervention: P. aeruginosa positive during the year of enrollment
Number of subjects: 484
Study 26288390 — intervention group
Group type: EXPERIMENTAL
Intervention: Crackles or wheeze during the year of enrollment
Number of subjects: 484
Study 26288390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's education of high school or less
Number of subjects: 484
Study 26288390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother smoked during pregnancy
Number of subjects: 484
Study 26290644 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR)
Number of subjects: 1057
Study 26290644 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Number of subjects: 1057
Study 26290644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BOC and TVR
Number of subjects: 1057
Study 26291023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1
Study 26291296 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing for patients with periodontitis (PD ≥4 to <7 mm)
Number of subjects: 168
Study 26291296 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α agents in patients with AS
Number of subjects: 168
Study 26291296 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 168
Study 26291753 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOS criteria fulfilled (125 patients)
Number of subjects: 831
Study 26291753 — intervention group
Group type: COMPARATOR
Intervention: Non-ACOS COPD patients
Number of subjects: 831
Study 26291916 — intervention group
Group type: EXPERIMENTAL
Intervention: Health insurance outreach HIT tools implemented in CHCs
Number of subjects: 34867
Study 26291916 — intervention group
Group type: COMPARATOR
Intervention: Matched control sites (no intervention)
Number of subjects: 34867
Study 26292027 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/Ad vaccine
Number of subjects: 15
Study 26292027 — intervention group
Group type: COMPARATOR
Intervention: AdCA vaccine
Number of subjects: 15
Study 26292221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 2 mg (Cohort 1)
Number of subjects: 12
Study 26292221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg (Cohort 2)
Number of subjects: 12
Study 26292221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone
Number of subjects: 12
Study 26292221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 12
Study 26292257 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum pre-erythrocytic antigens (21 identified)
Number of subjects: 0
Study 26292257 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC from RAS-immunized volunteers
Number of subjects: 0
Study 26292583 — intervention group
Group type: EXPERIMENTAL
Intervention: XPF cap (barium sulfate/bismuth oxide layered cap)
Number of subjects: 11
Study 26292583 — intervention group
Group type: COMPARATOR
Intervention: Ambient control
Number of subjects: 11
Study 26292583 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside left
Number of subjects: 11
Study 26292583 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside center
Number of subjects: 11
Study 26292583 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside right
Number of subjects: 11
Study 26292583 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside left vs Outside left
Number of subjects: 11
Study 26292583 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside center vs Outside center
Number of subjects: 11
Study 26292583 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside left vs Outside right
Number of subjects: 11
Study 26293153 — intervention group
Group type: EXPERIMENTAL
Intervention: Elder-friendly Approaches to the Surgical Environment (EASE) interventions
Number of subjects: 560
Study 26293153 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE interventions
Number of subjects: 560
Study 26293470 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated electronic reminders for earlier switching from i.v. to p.o. antibiotics
Number of subjects: 22863
Study 26293470 — intervention group
Group type: COMPARATOR
Intervention: No reminders (control group)
Number of subjects: 22863
Study 26293568 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartCare services with remote monitoring and health care services in addition to existing treatment.
Number of subjects: 0
Study 26293568 — intervention group
Group type: COMPARATOR
Intervention: Existing outpatient treatments (control group).
Number of subjects: 0
Study 26293568 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartCare services (intervention group).
Number of subjects: 0
Study 26293568 — intervention group
Group type: COMPARATOR
Intervention: Existing treatment (control group).
Number of subjects: 0
Study 26293760 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial LVEF <0.30
Number of subjects: 100
Study 26293760 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LVEF ≥0.30 and LVEDD <6.0 cm
Number of subjects: 100
Study 26293760 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF at study entry
Number of subjects: 100
Study 26293760 — intervention group
Group type: EXPERIMENTAL
Intervention: Major cardiovascular events (death, transplantation, or LV assist device)
Number of subjects: 100
Study 26293760 — intervention group
Group type: EXPERIMENTAL
Intervention: Race (black)
Number of subjects: 100
Study 26293760 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDD ≥6.0 cm
Number of subjects: 100
Study 26293760 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation after 6 weeks post-partum
Number of subjects: 100
Study 26293760 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF recovery
Number of subjects: 100
Study 26294723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin plus cyclophosphamide with ofatumumab
Number of subjects: 0
Study 26296092 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (300mg once-daily for 14 or 21 days per 28-day cycle)
Number of subjects: 59
Study 26296092 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (200mg twice-daily for 14 or 21 days per 28-day cycle)
Number of subjects: 59
Study 26296092 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (200mg twice-daily for 21 days per 28-day cycle)
Number of subjects: 59
Study 26296092 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (300mg once-daily for 21 days per 28-day cycle)
Number of subjects: 59
Study 26296092 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (extended dosing)
Number of subjects: 59
Study 26296295 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40mg once daily combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks)
Number of subjects: 16
Study 26296295 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 50mg once daily combined with paclitaxel 80mg/m(2) (days 1, 8 and 15 every four weeks)
Number of subjects: 16
Study 26296295 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib and paclitaxel combination
Number of subjects: 16
Study 26296371 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE) treatment of the prostate
Number of subjects: 16
Study 26296473 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of anti-mPLA2R1 autoantibodies
Number of subjects: 41
Study 26296473 — intervention group
Group type: EXPERIMENTAL
Intervention: rbPLA2R1 ELISA
Number of subjects: 41
Study 26296473 — intervention group
Group type: EXPERIMENTAL
Intervention: mPLA2R1 ELISA
Number of subjects: 41
Study 26296952 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 (10 mg/m(2), 16·7 mg/m(2), 24·6 mg/m(2), 33 mg/m(2), 55 mg/m(2), 83 mg/m(2))
Number of subjects: 25
Study 26296952 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001 (16·7 mg/m(2))
Number of subjects: 25
Study 26297144 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mobilization protocol before, 6 and 24 h after surgery
Number of subjects: 23
Study 26297144 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position at 6 h after surgery
Number of subjects: 23
Study 26297144 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position at 24 h after surgery
Number of subjects: 23
Study 26297144 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position at 24 h after surgery
Number of subjects: 23
Study 26297176 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF, rituximab, fludarabine, and cyclophosphamide
Number of subjects: 15
Study 26297176 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF, rituximab, fludarabine, and mitoxantrone
Number of subjects: 15
Study 26297222 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus Interactive Cholesterol Advisory Tool (first 8 weeks)
Number of subjects: 123
Study 26297222 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 123
Study 26297810 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home sleep apnea test combined with transcutaneous partial pressure of carbon dioxide/oxygen saturation by pulse oximetry monitoring
Number of subjects: 81
Study 26299218 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard demographic, clinical, and echocardiographic variables collection
Number of subjects: 2750
Study 26299218 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic and biomarker analyses
Number of subjects: 2750
Study 26299381 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular indirect ophthalmoscopy (BIO) and digital retinal imaging
Number of subjects: 1257
Study 26299414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care with prescribed medications or other therapies
Number of subjects: 262
Study 26299436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at the third month after surgery (M3)
Number of subjects: 391
Study 26299436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain at the sixth month after surgery (M6)
Number of subjects: 391
Study 26299436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of neuropathic pain (up to M6)
Number of subjects: 391
Study 26300719 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 66
Study 26300719 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 66
Study 26300719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 66
Study 26300782 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day XOS for 8 weeks
Number of subjects: 29
Study 26300782 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 29
Study 26300790 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1 mA for 20 minutes over the left dorsolateral prefrontal cortex
Number of subjects: 60
Study 26300790 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 26300919 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid (875 mg/125 mg BID, n = 235)
Number of subjects: 472
Study 26300919 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (150 mg QID, n = 237)
Number of subjects: 472
Study 26300919 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid
Number of subjects: 472
Study 26300919 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid and Clindamycin
Number of subjects: 472
Study 26300945 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanfu herbal patch (SHP)
Number of subjects: 0
Study 26300945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26300945 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 0
Study 26300986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg daily, n=87)
Number of subjects: 174
Study 26300986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=87)
Number of subjects: 174
Study 26300987 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 119
Study 26300987 — intervention group
Group type: COMPARATOR
Intervention: Intensive lifestyle intervention
Number of subjects: 119
Study 26300987 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss
Number of subjects: 119
Study 26301100 — intervention group
Group type: EXPERIMENTAL
Intervention: Edratide 0.5 mg
Number of subjects: 340
Study 26301100 — intervention group
Group type: EXPERIMENTAL
Intervention: Edratide 1.0 mg
Number of subjects: 340
Study 26301100 — intervention group
Group type: EXPERIMENTAL
Intervention: Edratide 2.5 mg
Number of subjects: 340
Study 26301100 — intervention group
Group type: EXPERIMENTAL
Intervention: Edratide (all doses)
Number of subjects: 340
Study 26301100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 26301448 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone monotherapy
Number of subjects: 169
Study 26301448 — intervention group
Group type: COMPARATOR
Intervention: Risperidone discontinued
Number of subjects: 169
Study 26301448 — intervention group
Group type: COMPARATOR
Intervention: Risperidone continued
Number of subjects: 169
Study 26302380 — intervention group
Group type: COMPARATOR
Intervention: Expert opinion forecasting
Number of subjects: 24
Study 26302380 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical regression forecasting
Number of subjects: 24
Study 26302380 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS hidden Markov model forecasting
Number of subjects: 24
Study 26302738 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1
Study 26303401 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP)
Number of subjects: 60
Study 26303401 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60
Study 26304481 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual intramuscular and intra-arterial injection of bone marrow mononuclear cells harvested from the iliac crest
Number of subjects: 49
Study 26304646 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee confidence assessed using item Q3 of the Knee injury and Osteoarthritis Outcome Score
Number of subjects: 220
Study 26304646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain on walking
Number of subjects: 220
Study 26304646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of movement
Number of subjects: 220
Study 26304646 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor general health
Number of subjects: 220
Study 26304646 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength
Number of subjects: 220
Study 26304866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran treatment initiated within 24 hours of minor stroke, continued for 30 days.
Number of subjects: 53
Study 26304872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg once per day for 4 weeks on and 2 weeks off plus intravenous trebananib 10 mg/kg once per week (cohort A)
Number of subjects: 85
Study 26304872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg once per day for 4 weeks on and 2 weeks off plus intravenous trebananib 15 mg/kg once per week (cohort B)
Number of subjects: 85
Study 26305021 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of levobupivacaine 0.5 % (2 ml/h for 48 hours)
Number of subjects: 0
Study 26305021 — intervention group
Group type: COMPARATOR
Intervention: Saline (2 ml/h for 48 hours)
Number of subjects: 0
Study 26305790 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic belts
Number of subjects: 34
Study 26305790 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 26306290 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (dDAVP) administered by intravenous infusion in saline, 30-60 min before and 24 h after surgical resection.
Number of subjects: 20
Study 26306719 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical recovery from critical illness at 12 months, defined as being alive with Short Form-36 physical function score of at least 10 points, and not 10 or more points below baseline.
Number of subjects: 610
Study 26306719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality rates at different time points.
Number of subjects: 610
Study 26306719 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with physical recovery.
Number of subjects: 610
Study 26306819 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3 monthly (PP3M)
Number of subjects: 0
Study 26308175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 146
Study 26308175 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir with atazanavir/ritonavir
Number of subjects: 146
Study 26308285 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes (TILs) therapy
Number of subjects: 0
Study 26308596 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg
Number of subjects: 72
Study 26308596 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab 8 mg/kg
Number of subjects: 72
Study 26308635 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 585
Study 26308635 — intervention group
Group type: COMPARATOR
Intervention: No statin use
Number of subjects: 585
Study 26308942 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine monotherapy
Number of subjects: 120
Study 26308942 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA deficiency
Number of subjects: 120
Study 26308942 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA genetic analysis
Number of subjects: 120
Study 26308942 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring of gemcitabine
Number of subjects: 120
Study 26310525 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, holistic review of care needs delivered at home by a respiratory nurse 4 weeks post-discharge.
Number of subjects: 14
Study 26310525 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistructured interviews and group discussions with patients, carers, and professionals.
Number of subjects: 14
Study 26310525 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive approaches that foster independence.
Number of subjects: 14
Study 26310540 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent iron deficiency (serum ferritin ≤75 ng/mL)
Number of subjects: 90
Study 26310540 — intervention group
Group type: COMPARATOR
Intervention: Normal iron status (serum ferritin >75 ng/mL)
Number of subjects: 90
Study 26310596 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater alcohol involvement (measured by drinks per week, maximum drinks per day, frequency of heavy drinking, AUDIT-C, and alcohol problems)
Number of subjects: 508
Study 26310596 — intervention group
Group type: COMPARATOR
Intervention: Control for alternative sex-linked explanations (i.e., depression and drug use)
Number of subjects: 508
Study 26310837 — intervention group
Group type: EXPERIMENTAL
Intervention: CC rate 100-120/min and CC depth ≥ 60 mm (without mattress deflection correction)
Number of subjects: 104
Study 26310837 — intervention group
Group type: EXPERIMENTAL
Intervention: CC depth
Number of subjects: 104
Study 26310837 — intervention group
Group type: EXPERIMENTAL
Intervention: Deeper CC
Number of subjects: 104
Study 26310975 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7256 (200 mg QD to 2400 mg BID)
Number of subjects: 45
Study 26310975 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7256 (high dose levels >1200 mg BID)
Number of subjects: 45
Study 26310975 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7256
Number of subjects: 45
Study 26311446 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy
Number of subjects: 0
Study 26311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral scene-selective area (upper visual field)
Number of subjects: 0
Study 26311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral scene-selective region (lower visual field)
Number of subjects: 0
Study 26311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional imaging studies
Number of subjects: 0
Study 26311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivoxel response analysis
Number of subjects: 0
Study 26312070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin added-on to metformin
Number of subjects: 50
Study 26312070 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide added-on to metformin
Number of subjects: 50
Study 26312164 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir once-daily dosing regimens: 35/7 mg/kg for 10 to <15 kg, 600/100 mg for 15 to <30 kg, 675/100 mg for 30 to <40 kg, 800/100 mg for ≥40 kg.
Number of subjects: 0
Study 26312852 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir (8 g daily) for 6 months
Number of subjects: 28